Irvine, California, United States, November 2025 — Steve Sloan has been appointed as Chief Financial Officer (CFO) at JenaValve Technology, Inc., a pioneering medical device company specializing in next-generation transcatheter heart valve systems. With over two decades of experience leading global finance operations across the medical device and manufacturing industries, Steve brings strategic vision, financial discipline, and deep operational expertise to JenaValve’s executive leadership team.
Steve has been part of JenaValve Technology, Inc. for the past three years, most recently serving as Vice President of Finance, where he played a central role in driving the company’s financial strategy, reporting, and business operations. During this period, he supported the company’s rapid clinical and commercial progress, including the advancement of the Trilogy Heart Valve System, and strengthened financial processes to support JenaValve’s growth in the U.S. and global markets. His promotion to CFO reflects his consistent leadership in aligning financial governance with innovation-driven business objectives.
Before joining JenaValve, Steve served as Chief Financial Officer at Biomerica, Inc., where he oversaw corporate finance, SEC financial reporting, manufacturing, IT, and HR operations. His tenure at Biomerica was marked by strategic fiscal management and operational streamlining that enhanced overall profitability and efficiency.
Earlier, Steve spent over nine years at Medtronic, where he rose through key financial leadership roles including Divisional Finance Director, Senior Finance Manager, and Finance Manager. At Medtronic, he was responsible for financial oversight across eight global manufacturing sites generating $1.2 billion in revenue, managing a $500 million spend and $200 million in inventory. He also developed financial systems and key performance metrics that optimized cost structures and strengthened business agility.
Prior to Medtronic, Steve had a distinguished 14-year career at GE, where he held multiple finance roles including Finance Manager, Financial Planning & Analysis Manager, and Sourcing Finance Manager. He was responsible for managing multi-billion-dollar inventories, executing cost reduction strategies, and leading financial integration for acquisitions. His early global assignments as Internal Auditor across regions such as Japan, South Africa, and Europe provided him with an international perspective on financial governance and compliance.
About JenaValve Technology, Inc.
JenaValve Technology, Inc. is a global medical device company advancing the future of transcatheter heart valve therapy. Its flagship innovation, the JenaValve Trilogy Heart Valve System, is the first and only device approved in the EU for the minimally invasive treatment of severe, symptomatic aortic regurgitation (AR) and aortic stenosis.
Headquartered in Irvine, California, with offices in Leeds, U.K., and Munich, Germany, JenaValve is redefining cardiovascular care through breakthrough engineering and clinical excellence. The company has completed enrollment for its pivotal ALIGN-AR IDE Clinical Trial in the U.S., which will support a future PMA submission — potentially making the Trilogy System the first TAVR system in the U.S. indicated for the treatment of severe AR.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
